 |
|
|
|
 |
|
|
| Article 1 to 10 out of 34 concerning Innogenetics Group
|
-
Solvay Pharmaceuticals acquires Innogenetics
(11 Sep 2008)
Solvay Group holds 84.3% of Innogenetics shares
Solvay Pharmaceuticals S.A., a subsidiary of the Solvay Group, announced that it succeeded to acquire Innogenetics N.V. in a cash transaction valued at EUR 6.5 per share, representing EUR 200.7 million for 100% of the Innogenetics shares. The offer ...
-
Innogenetics grants GlaxoSmithKline Biologicals a license for use of HPV SPF10 genotyping technology in clinical studies on HPV
(03 Jul 2008)
Innogenetics announced that it has granted GlaxoSmithKline Biologicals (GSK) a worldwide non-exclusive restricted license to use its proprietary SPF10 technology in clinical and epidemiological human papillomavirus (HPV) vaccine studies. ...
-
Innogenetics achieves CE mark for new human papillomavirus (HPV) genotyping test
(04 Jun 2008)
Innogenetics announced that it has received CE marking for its new and expanded HPV genotyping test, the INNO-LiPA HPV Genotyping Extra. The new generation kit allows the genotyping of 28 different HPV genotypes, of which 18 are high-risk types for ...
-
Innogenetics announces definitive closure of GENimmune
(03 Jun 2008)
Innogenetics announced the final phase of its restructuring plan for the pharma division of GENimmune. In accordance with the collective labor agreement signed on May 8 with its social partners, the remaining 5 labor contracts will shortly be ...
-
Solvay Pharmaceuticals S.A. launches friendly bid to acquire Innogenetics
(29 Apr 2008)
Building on a successful R&D co-operation
Solvay Pharmaceuticals S.A., a subsidiary of Solvay, and Innogenetics N.V. jointly announced that Solvay Pharmaceuticals S.A. will make a conditional tender offer to acquire Innogenetics in a cash transaction valued at EUR 5.75 per share.Solvay ...
-
Innogenetics and Solvay Pharmaceuticals extend collaboration for biomarker discovery
(10 Apr 2008)
Innogenetics announced a 2-year extension of its longstanding research collaboration with Solvay Pharmaceuticals. Since November 1997, Solvay and Innogenetics have collaborated on a joint research program to explore new targets for Solvay's drug ...
-
Innogenetics announces the intention to restructure its subsidiary GENimmune
(14 Feb 2008)
Last year, Innogenetics decided to focus on the development and sales of diagnostic products, and GENimmune N.V. was incorporated as a fully owned subsidiary. GENimmune obtained assets of Innogenetics in the field of drug development. The strategy ...
-
Innogenetics secures key patent for hepatitis B drug resistance testing
(08 Feb 2008)
Innogenetics announced that the United States Patent Office has granted a key patent for hepatitis B drug resistance testing. This is the first granted US patent covering a critical mutation leading to hepatitis B viral drug resistance. US patent ...
-
GENimmune receives Orphan Medicinal Product Designation from European Commission for its hepatitis C monoclonal antibody
(13 Dec 2007)
GENimmune, the newly created biopharmaceutical subsidiary of Innogenetics, announced that its candidate hepatitis C monoclonal antibody has been granted Orphan Medicinal Product Designation by the European Commission. The product is under ...
-
Innogenetics concludes settlement and licensing agreement in the field of Hepatitis C diagnostics
(19 Oct 2007)
Innogenetics announced an agreement with Novartis on major licensing terms in the field of Hepatitis C Virus (HCV) diagnostics. According to the license agreement, Novartis grants Innogenetics a license to its Hepatitis C patent rights in the field ...
Additional information
Innogenetics Group
Gent, Belgium
Company
|
|
|
|
|
|
Top
